查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1854501

医疗设备报销市场按支付方、器材类型、器材分类、应用和最终用户划分－2025-2032年全球预测

Medical Devices Reimbursement Market by Payer Outlook, Device Type, Device Classification, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，医疗设备报销市场规模将达到 1,0586 亿美元，复合年增长率为 7.93%。

关键市场统计数据
基准年2024年 5748亿美元
预计年份：2025年 6182.5亿美元
预测年份 2032 10586亿美元
复合年增长率 (%) 7.93%

不断变化的健保报销环境、监管驱动因素和相关人员的奖励影响着医疗设备的采用和临床路径。

医疗设备报销格局正经历着重大变革，其驱动力包括支付方的优先事项、监管审查以及临床护理领域技术的快速创新。价值链上的相关人员正在重新评估医疗设备如何反映价值、如何做出报销决策，以及商业策略如何适应对临床结果和医疗总成本日益严格的审查。因此，製造商、医疗服务提供者和支付方正朝着以证据主导的路径迈进，这些路径强调长期绩效、互通性和以患者为中心的结果。

在实践中，这意味着医疗器材开发商必须超越技术规格，建构以可靠的卫生经济学证据和真实世界结果为支持的论述。同时，支付方正在扩展其评估新技术的标准，将疗效比较、预算影响和长期使用模式纳入考量。因此，报销策略不再是产品开发过程中的次要考虑因素，而是不可或缺的一部分。政策、采购和临床应用之间的相互作用将决定哪些创新能够转化为永续的临床实践。

以价值为导向的医疗服务、数位整合、供应链韧性以及监管预期如何重塑报销模式和商业策略

市场力量和政策转变正在引发医疗设备评估、采购和报销方式的变革，对製造商和支付者都提出了新的要求。以价值为导向的医疗改革和价格透明化倡议优先考虑可衡量的患者疗效和对总成本的影响，促使支付方和整合医疗服务网络倾向于选择能够在整个治疗过程中展现可衡量获益的器械。同时，数位医疗的整合和软体赋能的器材正在模糊传统产品的界限，因此需要建立新的报销机制，将软体更新、云端服务和数据主导的临床决策支援纳入考量。

此外，供应链韧性正从后勤部门层面转向策略性报销驱动因素。采购方如今在签订合约时，往往会将供应的连续性和国内采购纳入考量。监管机构对网路安全、互通性和上市后监测的重视，提高了市场准入的证据门槛。因此，临床证据的产生、真实世界绩效监测以及与支付方的互动策略正日益成为关键的成功因素。总而言之，这些动态正在重塑商业模式，并促使製造商、医疗服务提供者和支付者之间开展合作，共同设计能够协调各相关人员奖励的支付结构。

评估不断变化的关税压力将如何影响医疗设备产业的供应链、采购选择、定价对话和证据策略。

提高进口壁垒或改变关税结构的政策会对采购、製造、定价和支付方谈判产生连锁反应，但在全球化供应链普遍存在的医疗设备产业，这些影响尤其敏感。当零件、原材料或成品征收关税时，製造商将面临不断上涨的投入成本，必须做出策略决策，例如自行承担、转嫁给买家或重新调整供应链。为此，一些公司正在加速近岸外包、实现供应商多元化或进行垂直整合，以确保利润率和交货时间。这些营运调整往往会影响与医院和医疗系统的合约谈判，因为这些机构可能会寻求价格保护或与交付绩效挂钩的附加采购条件。

从报销角度来看，关税会使定价对话变得复杂，因为支付方通常根据临床和经济价值而非短暂的贸易政策波动来评估医疗设备。儘管如此，医疗设备采购成本的持续上涨可能会促使支付方优先考虑那些有望降低医疗总成本并改善长期疗效的替代疗法，从而更加关注单件医疗设备的采购成本和医疗设备利用率。此外，关税可能会奖励製造商透过减少再入院率、缩短住院时间和降低后续护理成本来证明其产品能够抵消成本。因此，随着关税带来的成本压力日益显现，证据生成策略和合约弹性对于维持医疗产品的可及性和普及率至关重要。

最后，关税将影响策略投资决策。资本配置将转向调整生产布局和提升分析能力，以量化价格变化如何影响健保报销谈判。透过主动模拟关税情境并将其纳入与支付方的讨论，製造商可以提供切实可行的缓解策略，并在贸易动态变化的过程中维持医疗覆盖范围。

将支付方类型、医疗设备类别、分类、临床用途和最终用户偏好与报销动态和采用路径联繫起来的精细细分洞察

细緻的细分框架清楚地揭示了报销压力点和市场推广机会的交会点。它首先分析了私人和公共支付方在支付理念上的差异：私人支付方通常强调管理式医疗路径和基于价值的合同，而公共支付方则更注重标准化的福利结构和监管合规。按产品类型（耗材/抛弃式、诊断影像设备、行动辅助设备和治疗设备）进行细分，突显了不同的商业性和实质需求。在耗材方面，注射器、针头和创伤护理产品通常以单价和供应可用性为竞争优势；而诊断成像设备，例如CT扫描仪、MRI系统、超音波诊断设备和X光系统，则需要大量的资本投资、互通性认证和长期服务合约。治疗设备包括透析设备、输液系统和呼吸治疗设备，其中呼吸治疗设备还包括氧气疗法设备和人工呼吸器，每种设备都有其独特的用途和临床证据要求。

器械分类也至关重要：I类器械通常比II类器械面临更轻的监管和研发负担，II类器械通常需要基于性能数据和预测数据获得批准。 III类创新器材通常需要严格的临床试验和广泛的上市后追踪。应用细分进一步区分了心臟病学、神经病学、肿瘤学和骨科等领域的支付方和临床优先事项。心臟病学分支，例如心臟节律管理和介入性心臟病循环系统，强调器械的长期性和减少併发症；而神经科分支，例如脑脊髓液管理和神经刺激，则要求持久的疗效和安全性监测。同时，在整形外科分支中，关节重组和脊椎手术器械强调恢復活动能力和长期植入物存活率。最后，终端使用者细分区分了门诊手术中心、家庭医疗保健和医院/诊所等部署管道，其中医院/诊所进一步细分为植入和门诊病人护理环境，这两种环境的采购方式、合约週期和使用动态存在显着差异。

要确保在这些相互交织的维度上实现持久覆盖和普及，就需要製定能够反映每个细分市场相关的技术概况、临床应用和购买行为的报销策略。

美洲、欧洲、中东和非洲以及亚太地区不同的支付方体系、采购实务和监管方式将如何塑造不同的打入市场策略

美洲、欧洲、中东和非洲以及亚太地区的区域驱动因素以独特的方式影响报销法规、采购行为和路径选择，为医疗器材製造商创造了不同的策略重点。在美洲，尤其是美国，报销决策深受私人支付方和公共计画等复杂因素的影响，价值论证、捆绑销售奖励和医院的购买力指南商业化策略。在拉丁美洲市场，不断变化的法规环境和对成本控制日益重视，往往需要采用适应性定价模式和区域合作。

在欧洲、中东和非洲，各国医疗保健体系各不相同。有些国家采用集中采购模式，这不仅创造了扩充性的竞标机会，也带来了报销标准差异所带来的挑战。各国卫生技术评估机构通常透过评估疗效比较和预算影响来确定医保覆盖范围，而区域监管协调工作则越来越重视上市后证据和器械可追溯性。在亚太地区，数位医疗的快速普及和政府主导的医疗基础设施投资正在推动对先进诊断影像、治疗设备和居家照护解决方案的需求。然而，打入市场策略必须根据当地的报销框架进行调整，这些框架涵盖了从完全公共资助的公共体係到公私混合模式的各种情况，製造商还必须应对各种註册要求和价格管制。

综上所述，这些区域差异需要製定差异化的商业化蓝图，使临床证据的产生、定价策略和供应链布局与区域报销优先事项和采购机制保持一致。

为什么领先的医疗器材製造商正在整合临床证据、数位化服务和供应链投资，以改善报销、价格一致性和长期市场接受度？

领先的医疗设备製造商正在整合临床证据产生、数位化服务和供应链韧性，以保持竞争力并确保获得良好的报销结果。现有医疗技术公司正在投资于整合硬体、软体和服务的一体化医疗解决方案，以期在改善患者预后和提高诊疗流程效率方面取得可衡量的进步，同时寻求与数位医疗创新者合作，以加速远距监测和远端医疗医疗模式的发展。这些策略正帮助企业将与支付方的沟通重点从单价转向长期价值，从而催生出诸如绩效合约和人群风险分担安排等新型合约机制。

同时，专注于大批量耗材的公司正优先考虑生产规模、成本控制和分销可靠性，以满足高频次的临床需求。资本密集型诊断影像和治疗平台製造商则优先考虑服务协议、生命週期管理和互通性，以保护装置量并为高价定价提供基础。各公司正在扩展其真实世界证据项目，利用索赔层面的分析、註册登记和上市后监测来证明安全性、比较疗效和经济影响。随着成熟企业和新兴企业寻求扩展临床数据能力、扩大地域覆盖范围并整合数位健康产品以满足支付方期望和医疗服务提供方工作流程，策略併购和合作也变得越来越普遍。

製造商可采取切实可行的策略性倡议，使证据、合约和营运弹性与支付方和提供者对持久可及性的期望保持一致。

行业领导者应采取整合方法，将证据生成、商业性合约和营运韧性相结合，以避免报销流程的复杂性并加速产品推广。首先，在产品开发早期阶段就应纳入卫生经济学和结果研究，以产生前瞻性研究设计和真实世界证据，从而消除支付方对长期价值和预算影响的担忧。其次，应与支付方和医疗系统合作，采用基于结果的协议和打包支付模式等合作合约模式，以分担风险并展现与整体医疗成本目标的一致性。第三，应透过供应商多元化、区域化生产选择以及合约保障措施来增强供应链韧性，从而确保供应的连续性并促进与买家进行价格稳定谈判。

此外，我们将投资于数位化准备和互通性，以支援远端监测、上市后监测和资料收集，从而证实临床效益的声明。我们将透过建构上市后监测系统和事件回应能力，加强监管和网路安全准备，使支付方和医疗服务提供者对器材安全性和资料完整性放心。最后，我们将制定适应当地报销环境的市场策略，使定价、循证依据和服务模式与公共和私人支付方的独特期望以及门诊、居家医疗和医院环境的采购动态相匹配。透过协同利用这些要素，製造商可以提高获得有利保险覆盖、协商永续价格和推动持久临床应用的能力。

一个透明的研究框架，包括相关人员访谈、监管和临床证据综合分析以及三角验证分析，以检验报销方面的见解。

本分析所依据的研究整合了政策审查、监管指南、临床文献和相关人员访谈，从而对报销动态提供了多角度的视角。主要资料来源包括对支付方决策者、医院采购负责人、临床医生和医疗器材商业化高阶主管的结构化访谈，以了解观点对证据要求、合约偏好和推广障碍的看法。次要资料来源包括对临床研究、卫生技术评估报告和监管文件的系统综述，以确定证据阈值和上市后义务。

分析方法将定性见解与索赔层面的定量讯号进行三角验证，以识别核保决策、使用趋势和支付方谈判策略中的重复模式。证据综合包括检验透过新型临床项目和支付模式实现差异化准入的医疗设备案例研究，以及探讨政策和贸易发展如何改变采购奖励的情境分析。我们始终强调资料来源、访谈通讯协定和纳入标准的可重复记录，以确保透明度。我们进行了敏感性检查，并由临床和报销专家进行同行评审，以验证解释的准确性，并确保结论反映真实的决策情境和可实施的策略。

本文综合阐述了整合证据产生、适应性合约和在地化客製化为何决定着医保报销的成功和临床应用。

支付方日益严格的审查、数位化创新以及供应链的迫切需求，共同为力求获得报销核准和广泛临床应用的医疗器材製造商带来了挑战和机会。成功越来越取决于能否证明产品具有显着的临床疗效、量化总成本影响，并提供能够同时满足公共和私人支付方需求的持久上市后监测承诺。那些将卫生经济规划融入产品开发、投资真实世界数据项目并采用灵活合约结构的公司，将更有能力应对复杂的医保报销流程并保持商业性成长。

同时，区域差异和细分市场的具体情况需要製定独特的策略，以尊重当地的采购惯例和临床工作流程。透过将产品设计、证据产生和商业模式与这些背景因素结合，製造商可以加速产品在目标细分市场和医疗环境中的应用。最终，将报销视为核心策略职能，并由临床、监管、商业和营运团队协同合作的公司，将确保更早获得市场准入、建立更牢固的支付方关係，以及实现更可预测的使用轨迹。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合真实世界证据以确保数位健康设备快速报销
  • 基于价值的定价模式的变化正在影响保险公司对新型诊断影像系统的承保范围。
  • 随着联邦医疗保险和医疗补助计划的扩展，远端患者监护报销代码应运而生
  • 为精准手术机器人争取高额报销率的谈判策略
  • 医疗技术评估方法对人工智慧诊断设备应用的影响
  • 扩大打包支付模式会影响整形外科植入手术的报销。
  • 监管改革简化了远端医疗医疗设备服务的编码和计费流程

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章医疗设备报销市场（按支付方划分）展望

  • 私人的
  • 公共

第九章 按器材类型分類的医疗设备报销市场

  • 耗材和抛弃式用品
    • 注射器和针头
    • 创伤护理产品
  • 诊断影像设备
    • 电脑断层扫描（CT）扫描仪
    • 磁振造影（MRI）设备
    • 超音波设备
    • X射线系统
  • 行动辅助设备
  • 治疗设备
    • 透析设备
    • 输液系统
    • 呼吸治疗装置
      • 氧气疗法设备
      • 人工呼吸器

第十章 按器材分类分類的医疗设备报销市场

  • 一级
  • II 类
  • 三级

第十一章 按应用分類的医疗设备报销市场

  • 心臟病学
    • 心臟节律管理
    • 介入性心臟病学器械
  • 神经病学
    • 脑脊髓液管理
    • 神经刺激设备
  • 肿瘤学
    • 化疗的实施
    • 放射治疗设备
  • 整形外科
    • 关节重组
    • 脊椎外科手术器械

第十二章医疗设备报销市场（依最终用户划分）

  • 门诊手术中心
  • 家庭医疗保健
  • 医院和诊所
    • 住院治疗
    • 门诊治疗

第十三章 各地区医疗设备报销市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章医疗设备报销市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国医疗设备报销市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AiM GmbH
    • Allianz SE
    • Anco Insurance
    • Anthem Insurance Companies, Inc.
    • Aviva PLC
    • BNP Paribas
    • CVS Health Corporation
    • European Med Tech and IVD Reimbursement Consulting Ltd.
    • Hamilton Leigh Ltd.
    • HUB International Limited
    • Humana Inc.
    • MCRA, LLC
    • mdiConsultants, Inc.
    • Medmarc Insurance Group
    • North American Science Associates, Inc.
    • Reliance Nippon Life Insurance Company
    • UnitedHealth Group
    • UnitedHealth Group Incorporated
    • WellCare Health Plans, Inc.
    • WS Value & Dossier GmbH
    • XIFIN, Inc.
Product Code: MRR-205091A88A65

The Medical Devices Reimbursement Market is projected to grow by USD 1,058.60 billion at a CAGR of 7.93% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 574.80 billion
Estimated Year [2025] USD 618.25 billion
Forecast Year [2032] USD 1,058.60 billion
CAGR (%) 7.93%

A concise orientation to the evolving reimbursement environment, regulatory drivers, and stakeholder incentives reshaping device adoption and clinical pathways

The reimbursement landscape for medical devices is undergoing a decisive transition driven by payer priorities, regulatory scrutiny, and rapid innovation in clinical care. Stakeholders across the value chain are re-evaluating how devices demonstrate value, how coverage determinations are made, and how commercial strategies must adapt to tighter scrutiny of clinical outcomes and total cost of care. Consequently, manufacturers, providers, and payers are converging around evidence-driven pathways that emphasize longitudinal performance, interoperability, and patient-centered outcomes.

In practice, this means that device developers must move beyond technical specifications to craft narratives supported by robust health economic evidence and real-world outcomes. Simultaneously, payers are expanding the criteria they use to assess new technologies, incorporating comparative effectiveness, budget impact, and long-term utilization patterns. As a result, reimbursement strategy has become an essential component of product development rather than an afterthought. The interplay between policy, procurement, and clinical adoption will determine which innovations translate into sustainable clinical practice.

How value-based care, digital integration, supply resilience, and regulatory expectations are jointly reshaping reimbursement models and commercial strategies

Market forces and policy shifts are triggering transformative changes in how medical devices are assessed, procured, and reimbursed, creating new imperatives for manufacturers and payers alike. Value-based care reforms and price transparency initiatives are prioritizing measurable patient outcomes and total cost impact, prompting payers and integrated delivery networks to favor devices that can demonstrate measurable benefits across episodes of care. In parallel, digital health integration and software-enabled devices are blurring traditional product boundaries, necessitating fresh reimbursement constructs that account for software updates, cloud services, and data-driven clinical decision support.

Moreover, supply chain resilience has shifted from a back-office concern to a strategic reimbursement factor; purchasers now often factor in supply continuity and domestic sourcing into contracting decisions. Regulatory emphasis on cybersecurity, interoperability, and post-market surveillance has increased the evidentiary bar for market access. Consequently, clinical evidence generation, real-world performance monitoring, and payer engagement strategies are converging as critical success factors. Taken together, these dynamics are reshaping commercial models and incentivizing collaborations between manufacturers, providers, and payers to co-design payment structures that align incentives across stakeholders.

Assessing how evolving tariff pressures can ripple through supply chains, procurement choices, pricing dialogues, and evidence strategies across the medical device sector

Policies that raise import barriers or change tariff structures create ripple effects through procurement, manufacturing, pricing, and payer negotiations, with particular sensitivity in the medical device sector where globalized supply chains are common. When tariffs are applied to components, raw materials, or finished devices, manufacturers face higher input costs and must make strategic decisions about absorbing costs, passing them to buyers, or rebalancing supply chains. In response, some companies accelerate nearshoring, diversify supplier portfolios, or increase vertical integration to insulate margins and delivery timelines. These operational adjustments frequently influence contract negotiations with hospitals and health systems, which may seek price protections or conditional purchasing tied to delivery performance.

From a reimbursement perspective, tariffs complicate pricing dialogues because payers typically evaluate devices based on clinical and economic value rather than transient trade policy fluctuations. Nevertheless, sustained increases in acquisition costs tend to trigger greater attention to per-procedure costs and device utilization rates, encouraging payers to favor alternatives that promise lower total cost of care or improved long-term outcomes. In addition, tariffs can amplify incentives for manufacturers to demonstrate cost offsets via reduced readmissions, shorter length of stay, or decreased downstream therapy costs. As a result, evidence-generation strategies and contractual flexibility become essential to preserve access and uptake when tariff-driven cost pressures emerge.

Finally, tariffs influence strategic investment decisions. Capital allocation shifts toward manufacturing footprint adjustments and analytics capabilities that quantify how price changes affect reimbursement conversations. By proactively modeling tariff scenarios and integrating them into payer discussions, manufacturers can present credible mitigation plans and preserve coverage pathways despite evolving trade dynamics.

Granular segmentation insights linking payer type, device category, classification, clinical application, and end-user setting to reimbursement dynamics and adoption pathways

A nuanced segmentation framework clarifies where reimbursement pressure points and adoption opportunities intersect, beginning with payer outlook distinctions across Private and Public coverage environments where private insurers often emphasize managed care pathways and value-based contracting while public payers focus on standardized benefit structures and regulatory compliance. Device type segmentation highlights distinct commercial and evidentiary needs across Consumables and Disposables, Diagnostic Imaging Equipment, Mobility Aids, and Therapeutic Devices; within consumables, syringes and needles and wound care products typically compete on unit cost and supply reliability, whereas diagnostic imaging equipment such as CT scanners, MRI systems, ultrasound devices, and X-ray systems require substantial capital investment, interoperability credentials, and long-term service agreements. Therapeutic devices encompass dialysis equipment, infusion systems, and respiratory therapy devices, and the respiratory therapy subset includes oxygen therapy equipment and ventilators, each of which has unique utilization patterns and clinical evidence requirements.

Device classification also matters: Class I items generally face lighter regulatory and evidentiary burdens compared with Class II devices that often require performance data and predicate-based clearance, and Class III innovations typically demand rigorous clinical trials and extensive post-market follow-up. The application segmentation further differentiates payer and clinical priorities across cardiology, neurology, oncology, and orthopedics. Cardiology subdivisions like cardiac rhythm management and interventional cardiology devices focus on longevity and complication reduction, while neurology areas such as cerebrospinal fluid management and neurostimulation demand durable outcomes and safety monitoring. Oncology segments split between chemotherapy administration and radiation therapy equipment, each tied to complex treatment pathways, whereas orthopedics covering joint reconstruction and spinal surgery devices center on mobility restoration and longer-term implant survivorship. Finally, end-user segmentation delineates channels of adoption between ambulatory surgical centers, home healthcare, and hospitals and clinics, with the latter further segmented into in-patient care and out-patient care settings that differ markedly in purchasing practices, contracting cycles, and utilization dynamics.

Across these intersecting dimensions, tailored reimbursement strategies must reflect the technical profile, clinical footprint, and purchasing behavior associated with each segment to secure durable coverage and uptake.

How contrasting payer systems, procurement customs, and regulatory approaches across the Americas, Europe Middle East & Africa, and Asia-Pacific dictate tailored market access strategies

Regional dynamics shape reimbursement rules, procurement behaviors, and pathway adoption in distinctive ways across the Americas, Europe Middle East & Africa, and Asia-Pacific, creating differing strategic priorities for device manufacturers. In the Americas, particularly within the United States, reimbursement decisions are heavily influenced by a complex mix of private insurers and public programs where value demonstration, bundling incentives, and hospital purchasing power guide commercialization tactics. Latin American markets in the region present variable regulatory environments and greater emphasis on cost-containment tactics, often requiring adaptable pricing models and regional partnerships.

In Europe, the Middle East & Africa, heterogeneous national health systems and centralized procurement in some countries create both opportunities for scalable tenders and challenges related to divergent reimbursement criteria. National health technology assessment bodies frequently shape coverage decisions by assessing comparative effectiveness and budget impact, and regional regulatory alignment efforts place additional emphasis on post-market evidence and device traceability. In the Asia-Pacific region, rapid adoption of digital health and government-led investment in health infrastructure drive demand for advanced imaging, therapeutic devices, and home-based care solutions. However, market access strategies must be tailored to local reimbursement frameworks, which range from fully funded public systems to mixed public-private models, and manufacturers must navigate variable registration requirements and pricing controls.

Taken together, these regional contrasts require differentiated commercialization blueprints that align clinical evidence generation, pricing strategies, and supply chain footprints with local reimbursement priorities and procurement mechanisms.

Why top device manufacturers are combining clinical evidence, digital services, and supply chain investments to secure coverage, pricing parity, and long-term adoption

Leading device manufacturers are consolidating capabilities across clinical evidence generation, digital services, and supply chain resilience to maintain competitive positioning and secure favorable reimbursement outcomes. Established medtech firms are investing in integrated care solutions that combine hardware, software, and services to create measurable improvements in patient outcomes and pathway efficiency, while also seeking partnerships with digital health innovators to accelerate remote monitoring and telehealth-enabled care models. These strategies help firms shift conversations with payers from unit price to value delivered over time, enabling novel contracting mechanisms such as performance-based agreements and population-level risk-sharing arrangements.

Concurrently, companies that specialize in high-volume consumables emphasize manufacturing scale, cost discipline, and distribution reliability to meet the demands of high-frequency clinical settings. Manufacturers of capital-intensive diagnostic imaging and therapeutic platforms are prioritizing service agreements, lifecycle management, and interoperability to protect installed bases and justify premium pricing. Across the board, firms are expanding real-world evidence programs, leveraging claims-level analyses, registries, and post-market studies to demonstrate safety, comparative effectiveness, and economic impact. Strategic M&A and collaboration are common as incumbents and emerging firms seek to augment clinical data capabilities, extend geographic reach, and integrate digital health offerings that align with payer expectations and provider workflows.

Practical strategic moves for manufacturers to align evidence, contracting, and operational resilience with payer and provider expectations for durable access

Industry leaders should adopt an integrated approach that aligns evidence generation, commercial contracting, and operational resilience to navigate reimbursement complexity and accelerate adoption. First, embed health economics and outcomes research early in product development to produce prospective study designs and real-world evidence capable of addressing payer concerns about long-term value and budget impact. Second, pursue collaborative contracting models with payers and health systems, including outcome-based arrangements and bundled payment approaches, to share risk and demonstrate alignment with total cost of care objectives. Third, strengthen supply chain resilience through supplier diversification, regional manufacturing options, and contractual safeguards that preserve continuity of supply and enable price stability discussions with buyers.

Furthermore, invest in digital enablement and interoperability to support remote monitoring, post-market surveillance, and data capture that substantiate claims about clinical benefit. Enhance regulatory and cybersecurity preparedness by building post-market surveillance systems and incident response capabilities that reassure payers and providers about device safety and data integrity. Lastly, tailor go-to-market strategies to local reimbursement environments by aligning pricing, evidence dossiers, and service models with the unique expectations of public and private payers as well as the purchasing dynamics of ambulatory, home care, and hospital settings. By operationalizing these elements in concert, manufacturers improve their ability to secure favorable coverage, negotiate sustainable pricing, and drive durable clinical adoption.

A transparent research framework combining stakeholder interviews, regulatory and clinical evidence synthesis, and triangulated analysis to validate reimbursement insights

The research underpinning this analysis synthesizes policy reviews, regulatory guidance, clinical literature, and stakeholder interviews to produce a multidimensional view of reimbursement dynamics. Primary inputs include structured interviews with payer decision-makers, hospital procurement leaders, clinicians, and device commercialization executives to capture perspectives on evidence requirements, contracting preferences, and adoption barriers. Secondary inputs involve systematic reviews of clinical studies, health technology assessment reports, and regulatory documents that illuminate evidentiary thresholds and post-market obligations.

Analytic methods rely on triangulation across qualitative insights and quantitative claims-level signals to identify recurring patterns in coverage decisions, utilization trends, and payer negotiation tactics. Evidence synthesis includes examination of case studies where devices achieved differentiated access through novel clinical programs or payment models, as well as scenario analysis to explore how policy or trade developments may alter procurement incentives. Throughout, emphasis is placed on reproducible documentation of data sources, interview protocols, and inclusion criteria to ensure transparency. Sensitivity checks and peer review by clinical and reimbursement experts were applied to validate interpretations and ensure that conclusions reflect realistic decision-making contexts and implementable strategies.

Synthesis of why integrated evidence generation, adaptive contracting, and regional customization determine reimbursement success and clinical adoption

The convergence of elevated payer scrutiny, digital innovation, and supply chain imperatives creates both challenge and opportunity for device manufacturers seeking reimbursement approval and widespread clinical adoption. Success increasingly hinges on the ability to demonstrate meaningful clinical outcomes, quantify total cost implications, and present durable post-market surveillance commitments that satisfy both private and public payers. Firms that integrate health economic planning into product development, invest in real-world data programs, and pursue flexible contracting arrangements will be best placed to navigate reimbursement complexity and sustain commercial growth.

In parallel, regional differentiation and segment-specific nuances require tailored strategies that respect local procurement practices and clinical workflows. By aligning product design, evidence generation, and commercial models with these contextual factors, manufacturers can accelerate uptake in targeted segments and settings. Ultimately, the companies that treat reimbursement as a core strategic function-coordinated across clinical, regulatory, commercial, and operations teams-will secure earlier access, stronger payer relationships, and more predictable utilization trajectories.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of real world evidence to secure accelerated reimbursement for digital health devices
  • 5.2. Shifts in value based pricing models impacting insurer coverage of novel diagnostic imaging systems
  • 5.3. Emergence of remote patient monitoring reimbursement codes under Medicare and Medicaid expansions
  • 5.4. Negotiation strategies for achieving premium reimbursement rates for precision surgical robots
  • 5.5. Impact of health technology assessment methodologies on adoption of AI enabled diagnostic devices
  • 5.6. Expansion of bundled payment models affecting reimbursement for orthopaedic implant procedures
  • 5.7. Regulatory changes streamlining coding and billing for telehealth enabled medical device services

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Medical Devices Reimbursement Market, by Payer Outlook

  • 8.1. Private
  • 8.2. Public

9. Medical Devices Reimbursement Market, by Device Type

  • 9.1. Consumables and Disposables
    • 9.1.1. Syringes & Needles
    • 9.1.2. Wound Care Products
  • 9.2. Diagnostic Imaging Equipment
    • 9.2.1. Computed Tomography (CT) Scanners
    • 9.2.2. Magnetic Resonance Imaging (MRI) Equipment
    • 9.2.3. Ultrasound Devices
    • 9.2.4. X-Ray Systems
  • 9.3. Mobility Aids
  • 9.4. Therapeutic Devices
    • 9.4.1. Dialysis Equipment
    • 9.4.2. Infusion Systems
    • 9.4.3. Respiratory Therapy Devices
      • 9.4.3.1. Oxygen Therapy Equipment
      • 9.4.3.2. Ventilators

10. Medical Devices Reimbursement Market, by Device Classification

  • 10.1. Class I
  • 10.2. Class II
  • 10.3. Class III

11. Medical Devices Reimbursement Market, by Application

  • 11.1. Cardiology
    • 11.1.1. Cardiac Rhythm Management
    • 11.1.2. Interventional Cardiology Devices
  • 11.2. Neurology
    • 11.2.1. Cerebrospinal Fluid Management
    • 11.2.2. Neurostimulation Devices
  • 11.3. Oncology
    • 11.3.1. Chemotherapy Administration
    • 11.3.2. Radiation Therapy Equipment
  • 11.4. Orthopedics
    • 11.4.1. Joint Reconstruction
    • 11.4.2. Spinal Surgery Devices

12. Medical Devices Reimbursement Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Home Healthcare
  • 12.3. Hospitals & Clinics
    • 12.3.1. In-patient Care
    • 12.3.2. Out-patient Care

13. Medical Devices Reimbursement Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Medical Devices Reimbursement Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Medical Devices Reimbursement Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AiM GmbH
    • 16.3.2. Allianz SE
    • 16.3.3. Anco Insurance
    • 16.3.4. Anthem Insurance Companies, Inc.
    • 16.3.5. Aviva PLC
    • 16.3.6. BNP Paribas
    • 16.3.7. CVS Health Corporation
    • 16.3.8. European Med Tech and IVD Reimbursement Consulting Ltd.
    • 16.3.9. Hamilton Leigh Ltd.
    • 16.3.10. HUB International Limited
    • 16.3.11. Humana Inc.
    • 16.3.12. MCRA, LLC
    • 16.3.13. mdiConsultants, Inc.
    • 16.3.14. Medmarc Insurance Group
    • 16.3.15. North American Science Associates, Inc.
    • 16.3.16. Reliance Nippon Life Insurance Company
    • 16.3.17. UnitedHealth Group
    • 16.3.18. UnitedHealth Group Incorporated
    • 16.3.19. WellCare Health Plans, Inc.
    • 16.3.20. WS Value & Dossier GmbH
    • 16.3.21. XIFIN, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PAYER OUTLOOK, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PAYER OUTLOOK, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE CLASSIFICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE CLASSIFICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. MEDICAL DEVICES REIMBURSEMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. MEDICAL DEVICES REIMBURSEMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MEDICAL DEVICES REIMBURSEMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PAYER OUTLOOK, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PAYER OUTLOOK, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SYRINGES & NEEDLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SYRINGES & NEEDLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SYRINGES & NEEDLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SYRINGES & NEEDLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SYRINGES & NEEDLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SYRINGES & NEEDLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY WOUND CARE PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY WOUND CARE PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY WOUND CARE PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY WOUND CARE PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY WOUND CARE PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY WOUND CARE PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ULTRASOUND DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ULTRASOUND DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ULTRASOUND DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ULTRASOUND DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ULTRASOUND DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ULTRASOUND DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY X-RAY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY X-RAY SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY X-RAY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY X-RAY SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY X-RAY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY X-RAY SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MOBILITY AIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MOBILITY AIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MOBILITY AIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MOBILITY AIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MOBILITY AIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MOBILITY AIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIALYSIS EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIALYSIS EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIALYSIS EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIALYSIS EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIALYSIS EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIALYSIS EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INFUSION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INFUSION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INFUSION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INFUSION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INFUSION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INFUSION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OXYGEN THERAPY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OXYGEN THERAPY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OXYGEN THERAPY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OXYGEN THERAPY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OXYGEN THERAPY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OXYGEN THERAPY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY VENTILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY VENTILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY VENTILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY VENTILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY VENTILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY VENTILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE CLASSIFICATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE CLASSIFICATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CEREBROSPINAL FLUID MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CEREBROSPINAL FLUID MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CEREBROSPINAL FLUID MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CEREBROSPINAL FLUID MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CEREBROSPINAL FLUID MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CEREBROSPINAL FLUID MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROSTIMULATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROSTIMULATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROSTIMULATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROSTIMULATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROSTIMULATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROSTIMULATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CHEMOTHERAPY ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CHEMOTHERAPY ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CHEMOTHERAPY ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CHEMOTHERAPY ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CHEMOTHERAPY ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CHEMOTHERAPY ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RADIATION THERAPY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RADIATION THERAPY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RADIATION THERAPY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RADIATION THERAPY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RADIATION THERAPY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RADIATION THERAPY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY JOINT RECONSTRUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY JOINT RECONSTRUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY JOINT RECONSTRUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY JOINT RECONSTRUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY JOINT RECONSTRUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY JOINT RECONSTRUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SPINAL SURGERY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SPINAL SURGERY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SPINAL SURGERY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SPINAL SURGERY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SPINAL SURGERY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SPINAL SURGERY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY IN-PATIENT CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY IN-PATIENT CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY IN-PATIENT CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY IN-PATIENT CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY IN-PATIENT CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY IN-PATIENT CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OUT-PATIENT CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OUT-PATIENT CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OUT-PATIENT CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OUT-PATIENT CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OUT-PATIENT CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OUT-PATIENT CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PAYER OUTLOOK, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PAYER OUTLOOK, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE CLASSIFICATION, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE CLASSIFICATION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD